An interventional study of Inspiratory muscle training in Early Stage Breast Carcinoma and Dyspnea, sponsored by Ohio State University Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Ohio State University Comprehensive Cancer Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 214 studies in Dyspnea with a site in United States — 31 open to participants now, 37 under way, 1 of them phase 3. Dyspnea · United States.
Among the 214 studies in Dyspnea with a site in United States, this one is the 63rd largest by planned enrollment of the 151 interventional ones that give a count, is one of 11 that started in 2026, is one of 84 with no phase, reaches primary completion later than 11 of the 36 other live ones, and was the 204th registered.
895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.
Browse Dyspnea studies →31 of the 214 studies in Dyspnea with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18–75 · Healthy volunteers
Pfizer · Sites in United States
Ages 18+
Hackensack Meridian Health · Sites in United States
Ages 27 wk–34 wk
Joseph C. Wu · Sites in United States
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
214 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 40 · Phase 3 16 · Phase 4 12
First in 1999; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 58 is above the median of 50 across 588 interventional studies indexed under Dyspnea.
Median enrollment 36 across the 151 interventional studies, 93 across the 62 observational. Of the 162 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 214 have an industry lead sponsor. The 10 most frequent:
Ohio State University Comprehensive Cancer Center is the lead sponsor of 376 studies on the registry; 82 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 19 (50%) have results posted.
Ohio State University Comprehensive Cancer Center has 2 studies filed under Dyspnea — fewer than ten, so there is no comparison to draw.
13 of the studies in Dyspnea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05866952Tufts Medical CenterVentilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection | 2026-12 |
| NCT07386444Ohio State University Comprehensive Cancer CenterInspiratory Muscle Training for Breast Cancer Patients on Chemotherapy | 2026-12-31 |
| NCT06684119Children's Hospital Los AngelesPediatric Positive End Expiratory Pressure (PEEP) Titration Using Electrical Impedence Tomography (EIT) | 2027-01-01 |
| NCT06524856University of NebraskaThe Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser) | 2027-03-01 |
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
Add all 13 to your calendar (.ics) → With an account.
Among the 214 studies in Dyspnea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial studies whether breathing exercises for the muscles that help with breathing air in, inspiratory muscle training (IMT), works to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage breast cancer (BC). Cancer and/or treatments for BC can directly result in muscle wasting that involves breathing muscles, skeletal muscles or heart muscles. Pain, weakness, shortness of breath, and side effects of cancer treatment may lead to lower physical activity levels. IMT involves breathing exercises using a small hand-held device. The device makes it a little harder to breathe in, which may help strengthen breathing muscles. IMT may be an effective way to improve breathing muscle strength, shortness of breath, and physical activity levels in women who are receiving chemotherapy for early-stage BC.
PRIMARY OBJECTIVE: To investigate the effects of 8 weeks of IMT on inspiratory muscle strength, exertional dyspnea, and physical activity levels among women undergoing chemotherapy for BC.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients complete three sets of fifteen repetitions per session of low-intensity IMT over 15-20 minutes four days a week for 8 weeks.
ARM 2: Patients complete three sets of fifteen repetitions per session of high-intensity IMT over 15-20 minutes four days a week for 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients complete three sets of fifteen repetitions per session of low-intensity IMT over 15-20 minutes four days a week for 8 weeks.
Behavioral: Inspiratory muscle training
Patients complete three sets of fifteen repetitions per session of high-intensity IMT over 15-20 minutes four days a week for 8 weeks.
Behavioral: Inspiratory muscle training
Training of respiratory muscles
Maximum inspiratory pressure
Measure of the strength of the inspiratory muscles. Units: cm H20
Time frame: Baseline to 8 weeks
Physical activity levels
Number of steps/day averaged weekly.
Time frame: Baseline to 8 weeks
Modified Medical Research Council Dyspnea scale rating
Patients will indicate the extent to which their dyspnea affects mobility using a one question 1-5 scale; higher scores indicate greater respiratory disability.
Time frame: Baseline to 8 weeks
Dyspnea 12 score
Questionnaire consists of 12 descriptor items such as "I feel short of breath" and "my breathing is uncomfortable" with each item rated on a scale of none (0), mild (1), moderate (2), or severe (3). Individual items are summed to generate a total score (0 to 36), with a higher score indicating worse dyspnea
Time frame: Baseline to 8 weeks
RAND-36 Quality of life
8 subdomains will be scored 0-100 with higher scores reflecting better perceived quality of life.
Time frame: Baseline to 8 weeks
FACIT-F
Version 4 is a 40-item measure that will be used to assess self-reported fatigue and its impact on daily activities and function over the past 7 days. It is a 5-point Likert-type scale with five subdomains including physical well-being, social/family well-being, emotional well-being, functional well-being, and fatigue yielding a total score from 0-52.
Time frame: Baseline to 8 weeks
Relative dose intensity of chemotherapy
Will record the relative dose intensity of chemotherapy for each participant. The relative dose intensity will be averaged for analysis.
Time frame: At 8 weeks
Plan to share: Yes — Deidentified data will be freely available if requested. The privacy and rights of the participants will be protected.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will become available after data collection is complete for up to 3 years.
Access criteria: Deidentified data will be made available on request following approved data use agreements between institutions.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.
Of 268 non-industry interventional studies with no phase under Dyspnea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 10 months is below that.
Counting every sponsor, half of 284 studies reached it within 13 months; a quarter within 6 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ohio State University Comprehensive Cancer Center →